![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, May 15, 2017 6:10:02 PM
And the IP is valued at zero? The collective market cap of the pdl portion of the five players has got to be over $100 bil and with IP smack dab in the middle of the I-O contest/war, there is zero value for the PPHM IP?
IMO once the clouds go away, the institutions will play. So what are the clouds?
http://peregrineinc.com/images/stories/pdfs/aacr2017kallinteris.pdf
Among patients who received subsequent immunotherapy, a significant improvement in OS was observed for patients in the D+B compared to D+P; HR=0.43, p=0.005. No difference in OS was observed between the two treatment groups for patients who did not receive subsequent immunotherapy. Analysis by both IFN-? and SACT-IO classifications confirmed a statistically significant difference in OS favoring the D+B group among patients with low pretreatment IFN-? who received subsequent IO (HR= 0.24, p<0.001). No OS difference was observed between D+B and D+P for patients with high pretreatment IFN-? regardless of subsequent IO. These data support the mechanistic hypothesis that bavituximab may modulate immune response to enhance the activity of immunotherapy agents. Clinical trials combining bavituximab and immunotherapy agents such as checkpoint inhibitors are planned.
http://peregrineinc.com/images/stories/pdfs/aacr2017hirschhorn.pdf
Anti-OX40 (OX86) activate transferred anti-melanoma CD4+ T cell systemically. The CD4+ T cells migrate to tumor and melanocyte-rich tissues such as ear pinnae. This causes tumor regression but also triggers inflammatory destruction of healthy tissues.
• PS targeting decreases tumor-induced immunosuppression. Transferred antimelanoma CD4+ T cells migrate to tumors and promote tumor regression without offtarget side effects.
• PS targeting is a desirable strategy that can improve the potency of anti-tumor strategies with known clinical off-target effects such as adoptive T cell transfer.
• PS targeting can be combined with CAR T cells to enhance anti-tumor potential.
http://peregrineinc.com/images/stories/pdfs/aacr2017budhu.pdf
• Irradiation of B16 melanoma tumors causes an increase in Phosphatidylserine expression on the surface of both tumor and immune cells.
• mch1N11 in combination with RT or triple combination with mch1N11, RT, and anti-PD-1 led to a significant reduction in tumor burden and greater overall survival benefit.
• Analysis of systemic immune responses in the spleen and draining lymph nodes revealed an increase in CD8 T cell activation, effector cytokine production and differentiation into effector memory cells in the triple combination of RT, mch1N11, and anti-PD-1.
• Analysis of local immune responses in the tumors of treated animals revealed an increase in tumor
associated macrophages and a shift in macrophage polarization towards an M1 pro-inflammatory phenotype after treatment with RT and mch1N11.
• Gene expression analysis of myeloid cells isolated from tumors and draining lymph nodes 2 and 5 days after treatment with RT and mch1N11 show a decrease in expression of anti-inflammatory genes and and increase in expression of pro-inflammatory genes.
• Our data will potentially inform the design of clinical studies combining PS targeting with radiation therapy and/or checkpoint blockade
Recent CDMO News
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM